Novartis (NVS) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free NVS Stock Alerts $97.44 -1.62 (-1.64%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNovartis AG (NYSE:NVS) Shares Sold by Syon Capital LLCmarketbeat.com - April 26 at 4:31 PMNovartis (NYSE:NVS) PT Raised to $116.00americanbankingnews.com - April 26 at 5:40 AMNovartis (NYSE:NVS) Shares Gap Up to $95.12americanbankingnews.com - April 25 at 5:44 AMQ3 2025 EPS Estimates for Novartis AG (NYSE:NVS) Decreased by Analystamericanbankingnews.com - April 25 at 2:36 AMCompany News for Apr 24, 2024finance.yahoo.com - April 24 at 12:29 PMNovartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - April 24 at 12:29 PMBMO Capital Markets Boosts Novartis (NYSE:NVS) Price Target to $116.00marketbeat.com - April 24 at 12:11 PMFDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumorsfinance.yahoo.com - April 24 at 7:29 AMNovartis AG (NYSE:NVS) Expected to Post Q3 2025 Earnings of $1.98 Per Sharemarketbeat.com - April 24 at 6:49 AMFY2026 EPS Estimates for Novartis AG Boosted by Analyst (NYSE:NVS)americanbankingnews.com - April 24 at 2:56 AMNovartis, Medicines for Malaria Say Treatment for Babies Shows Efficacymarketwatch.com - April 24 at 2:29 AMFDA Approves Novartis' Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumorsmarkets.businessinsider.com - April 24 at 2:29 AMNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babiesglobenewswire.com - April 24 at 12:30 AMNovartis beats top-line and bottom-line estimates; raises FY24 outlookmsn.com - April 23 at 9:29 PMWhy Novartis Stock Topped the Market on Tuesdayfool.com - April 23 at 6:25 PMPolaris, Inc. (PII) Q1 2024 Earnings Call Transcriptseekingalpha.com - April 23 at 4:29 PMNovartis raises full-year sales and profit guidance after strong Q1proactiveinvestors.com - April 23 at 2:10 PMNVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024investorplace.com - April 23 at 2:02 PMNovartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumorsglobenewswire.com - April 23 at 1:42 PMNovartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climbinvestopedia.com - April 23 at 12:30 PMNovartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024marketbeat.com - April 23 at 12:09 PMNovartis: Q1 Earnings Snapshotsfgate.com - April 23 at 11:28 AMNovartis Q1 Profit Rises, Tops Estimates; Lifts FY24 View; Proposes Giovanni Caforio As New Chairmarkets.businessinsider.com - April 23 at 11:28 AMNovartis shares jump as drugmaker boosts outlookmsn.com - April 23 at 11:28 AMNovartis: Strong Start To The Year With Beat-And-Raise First Quarter Resultsseekingalpha.com - April 23 at 11:28 AMNVS Earnings: Novartis Beats Q1 Estimates, Raises Outlookmsn.com - April 23 at 11:28 AMNovartis raises full-year guidance on Q1 beat, drug salesfinance.yahoo.com - April 23 at 11:28 AMNovartis Ag (NVS) Q1 2024 Earnings Call Transcriptfool.com - April 23 at 11:28 AMNovartis AG 2024 Q1 - Results - Earnings Call Presentationseekingalpha.com - April 23 at 7:38 AMAnalysts Offer Predictions for Novartis AG's FY2026 Earnings (NYSE:NVS)marketbeat.com - April 23 at 6:31 AMShares of Novartis climb 4.8% on raised guidance, better-than-expected resultscnbc.com - April 23 at 3:35 AMNovartis lifts FY guidance after Q1 results beat expectationsreuters.com - April 23 at 1:09 AMNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raisedglobenewswire.com - April 23 at 1:00 AMNovartis (NVS) Set to Announce Quarterly Earnings on Tuesdaymarketbeat.com - April 22 at 9:46 AMNovartis Investors to Eye Outlook, Key Drugs at Earnings -- Earnings Previewmarketwatch.com - April 22 at 8:59 AMNovartis’ Multiple Sclerosis drug is effective for up to six years, study revealsmsn.com - April 19 at 9:33 AM2 High-Yield Dividend Stocks to Buy and Hold for 10 Yearsfool.com - April 17 at 9:30 AMNovartis : Six-Year Study Reveals Benefits Of Kesimpta In Newly Diagnosed Relapsing MS Patientsmarkets.businessinsider.com - April 17 at 6:50 AMNovartis' Fabhalta Demonstrates Significant Proteinuria Reduction In IgA Nephropathy Patientsmarkets.businessinsider.com - April 16 at 2:37 AMNovartis Gets Priority Review for Kidney Disease Treatmentmarketwatch.com - April 15 at 4:36 PMNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)prnewswire.com - April 15 at 2:00 PMNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)globenewswire.com - April 15 at 2:00 PMBristol John W & Co. Inc. NY Sells 32,654 Shares of Novartis AG (NYSE:NVS)marketbeat.com - April 14 at 3:45 PMTriasima Portfolio Management inc. Purchases 12,170 Shares of Novartis AG (NYSE:NVS)marketbeat.com - April 13 at 3:21 PMNovartis AG (NYSE:NVS) Shares Bought by NewEdge Wealth LLCmarketbeat.com - April 12 at 9:03 PMTraders Buy Large Volume of Call Options on Novartis (NYSE:NVS)marketbeat.com - April 11 at 11:37 AMArvinas, Novartis in ARV-766 Prostate Cancer License Pactmarketwatch.com - April 11 at 9:59 AMNovartis enters into licensing deal for Arvinas’ cancer drug worth up to $1.01 billionmsn.com - April 11 at 9:59 AMBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Optionsinvestors.com - April 11 at 9:17 AMSequoia Financial Advisors LLC Has $3.95 Million Stake in Novartis AG (NYSE:NVS)marketbeat.com - April 11 at 7:42 AM Get Novartis News Delivered to You Automatically Sign up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> NVS Media Mentions By Week NVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVS News Sentiment▼0.370.32▲Average Medical News Sentiment NVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVS Articles This Week▼4310▲NVS Articles Average Week Get Novartis News Delivered to You Automatically Sign up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABT News AZN News PFE News SNY News ABBV News VRTX News REGN News BMY News GSK News MRK News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NVS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
